MedPath

BI-706321

Generic Name
BI-706321

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-01-10
Last Posted Date
2024-08-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT05183360
Locations
🇯🇵

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Phase 2
Terminated
Conditions
Crohn Disease
Interventions
First Posted Date
2021-07-27
Last Posted Date
2024-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
49
Registration Number
NCT04978493
Locations
🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

Southern Star Research Institute, LLC, San Antonio, Texas, United States

🇺🇸

University of Utah Health Sciences Center, Salt Lake City, Utah, United States

and more 46 locations

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-01-19
Last Posted Date
2021-05-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT04714073
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2019-06-03
Last Posted Date
2020-12-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
61
Registration Number
NCT03971695
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath